PTC Therapeutics, Inc. · 完全回答書（NDA 220049）

出典の抜粋

ADMINISTRATION ¢ YN U.S. FOOD & DRUG NDA 220049 COMPLETE RESPONSE PTC Therapeutics, Inc. Attention: Aparna Geddam, MS Director, Global Regulatory Strategy 500 Warren Corporate Center Drive Warren, NJ 07059 Dear Aparna Geddam: Please refer to your new drug application (NDA) oe or vatiquinone oral capsules, oe We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form. We have described our reasons for this action below and, where possible, our recommendations to address these issues. CLINICAL/BIOSTATISTICS 1. After a detailed review of your application, we have concluded that the data do not demonstrate substantial evidence of effectiveness (SEE) for vatiquinone in the treatment of Friedreich’s Atax

openFDA